Rheumatology · Inflammatory Myopathies
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
The hallmark clinical triad of anti-synthetase syndrome consists of inflammatory myopathy, interstitial lung disease (ILD), and inflammatory arthritis.
The most specific and pathognomonic autoantibody associated with this syndrome is anti-Jo-1 (anti-histidyl-tRNA synthetase).
Patients frequently present with mechanic's hands, characterized by hyperkeratotic, fissured, and dirty-appearing skin on the palmar aspects of the fingers.
Interstitial lung disease is the primary determinant of morbidity and mortality in anti-synthetase syndrome and often presents as progressive exertional dyspnea and dry cough.
Physical examination often reveals Raynaud phenomenon and non-erosive, symmetric polyarthritis involving the small joints of the hands.
Laboratory evaluation typically demonstrates elevated creatine kinase (CK) levels and aldolase reflecting underlying muscle inflammation.
First-line treatment for systemic manifestations involves systemic corticosteroids, often requiring the addition of steroid-sparing agents like mycophenolate mofetil or rituximab for refractory ILD.
Vignette unlocked
A 52-year-old woman presents to the clinic with a 3-month history of progressive shortness of breath and joint pain. Physical examination reveals symmetrical swelling of the MCP and PIP joints, along with thickened, cracked skin on the tips of her fingers. Auscultation of the lungs reveals bibasilar crackles. Laboratory studies show an elevated creatine kinase level of 1,200 U/L and a positive anti-Jo-1 antibody titer.
What is the most likely diagnosis?
Anti-synthetase syndrome
The patient presents with the classic triad of inflammatory myopathy (elevated CK), ILD (crackles), and arthritis, combined with the pathognomonic 'mechanic's hands' and anti-Jo-1 antibodies.
Full handout
High yield triage
Etiology / Epidemiology
Rare autoimmune subset of idiopathic inflammatory myopathy; anti-Jo-1 antibodies are the hallmark.
Clinical Manifestations
Classic triad: mechanic's hands, interstitial lung disease (ILD), and inflammatory myositis.
Diagnosis
Anti-Jo-1 antibody (anti-histidyl-tRNA synthetase) is the diagnostic gold standard.
Treatment
Corticosteroids are first-line; avoid methotrexate if significant ILD is present.
Prognosis
ILD is the primary driver of mortality; monitor with serial PFTs.
Full handout
Epidemiology & Etiology
This syndrome is a distinct subset of idiopathic inflammatory myopathies, most commonly seen in middle-aged adults. It is strongly associated with the presence of anti-aminoacyl-tRNA synthetase antibodies. Genetic predisposition and environmental triggers are suspected but remain poorly defined.
Pertinent Anatomy
The condition primarily targets the skeletal muscle (proximal weakness) and the pulmonary interstitium. Involvement of the distal extremities leads to the characteristic skin changes on the palmar surfaces.
Pathophysiology
Autoantibodies target cytoplasmic enzymes involved in protein synthesis, triggering systemic inflammation. The resulting immune complex deposition leads to myositis and progressive fibrosing alveolitis. Chronic inflammation in the lungs often precedes or overshadows the muscular symptoms.
Clinical Manifestations
Patients present with the classic triad of mechanic's hands (hyperkeratotic, fissured skin on the palms), interstitial lung disease (ILD), and inflammatory myositis. Additional findings include Raynaud phenomenon, non-erosive arthritis, and fever. Acute respiratory failure is a critical red flag requiring immediate pulmonary evaluation.
Diagnosis
The anti-Jo-1 antibody is the most common and specific serologic marker. Diagnosis is confirmed via high-resolution CT (HRCT) of the chest to quantify the extent of ILD. Muscle biopsy may show perimysial necrosis, though it is not required if serology is positive.
Treatment
High-dose prednisone is the initial therapy for acute flares. For refractory cases or to facilitate steroid-sparing, rituximab or azathioprine are utilized. Methotrexate is generally avoided due to its potential for pulmonary toxicity, which can exacerbate underlying ILD.
Prognosis
The clinical course is dictated by the severity of interstitial lung disease. Patients require serial PFTs and DLCO monitoring to track pulmonary function decline. Early aggressive immunosuppression is vital to prevent irreversible pulmonary fibrosis.
Differential Diagnosis
Dermatomyositis: presence of Gottron papules and heliotrope rash
Polymyositis: lacks the characteristic mechanic's hands and ILD
Systemic Sclerosis: features sclerodactyly and esophageal dysmotility
Rheumatoid Arthritis: symmetric small joint erosive disease
Inclusion Body Myositis: distal muscle weakness and older age of onset